Jefferies has recently resumed Oncology Institute Inc (TOI) stock to Buy rating, as announced on February 26, 2024, according to Finviz. Earlier, on September 14, 2022, Guggenheim had initiated the stock to Buy, setting a price target of $7. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Oncology Institute Inc (TOI) Stock Trading Recap
On Tuesday, Oncology Institute Inc (TOI) stock saw a modest uptick, ending the day at $0.19 which represents a slight increase of $0.03 or 18.75% from the prior close of $0.16. The stock opened at $0.16 and touched a low of $0.16 during the day, reaching a high of $0.19. The volume of shares traded was 3.77 million exceeding the average volume of 1.14 million.
Sponsored
TOI Stock Performance and Moving Averages
In recent trading, Oncology Institute Inc (TOI) stock price has shown some volatility, fluctuating 27.33% over the last five trades and -35.68% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -57.17%, and it has plunged by -39.87% in the previous three months. Currently, TOI is trading at -6.60%, -29.91%, and -72.49% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, TOI, a Healthcare sector stock, is trading -92.28% below its 52-week high but remains 53.95% above its 52-week low. The Average True Range (ATR) (14 days) of 0.04 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Oncology Institute Inc’s Profitability and Valuation Ratios
Oncology Institute Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of -16.75% and a profit margin of -15.17%, with a gross margin of -57.17%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Oncology Institute Inc’s market capitalization stands at $14.58 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 0.04, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 0.94, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.00% of Oncology Institute Inc (TOI)’s shares, while financial institutions hold 22.59%.
